---
schema_version: "secwatch.filing_event.v1"
accession: "0001077183-23-000136"
form_type: "8-K"
ticker: "NEO"
cik: "0001077183"
company_name: "NEOGENOMICS INC"
filed_at: "2023-11-06T23:59:59+00:00"
generated_at: "2026-06-08T18:59:25.123911+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# NeoGenomics Q3 revenue up 18% to $152M, net loss halved, raises FY guidance

## Summary
- Consolidated revenue $152M (+18% YoY); Clinical Services $128M (+20%), Advanced Diagnostics $24M (+8%).
- Net loss decreased 50% to $19M; Adjusted EBITDA turned positive at $3M vs -$12M YoY.
- Raised FY23 revenue guidance to $585-592M (15-16% growth); Adj. EBITDA loss guidance improved to $4M-$1M loss.
- Cash and marketable securities $402M at quarter end.
- Adjusted Gross Profit Margin 44.2%, excluding amortization of acquired Inivata developed technology intangibles.

## SEC filing metadata
- accession: 0001077183-23-000136
- form_type: 8-K
- ticker: NEO
- cik: 0001077183
- company_name: NEOGENOMICS INC
- filed_at: 2023-11-06T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1077183/000107718323000136/0001077183-23-000136-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1077183/000107718323000136/neo-20231106.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001077183-23-000136
- JSON: https://secwatch.observer/filing/0001077183-23-000136.json
- Plain text: https://secwatch.observer/filing/0001077183-23-000136.txt

## Key facts
- Earnings Releases
  NEOGENOMICS INC reported its third fiscal quarter of 2023 results: revenue $152 million, net income $19 million. Guidance raised.
  - Period: its third fiscal quarter of 2023
  - Revenue: $152 million
  - Net income: $19 million
  - Guidance: raised
  - Result: reported results
  source text: as expressly set forth by specific reference in such filing. --- EX-99.1 (EX-99.1) --- NeoGenomics Reports Third Quarter 2023 Results Third Quarter Revenue Increased 18% to $152 Million Fort Myers, Florida (November 6, 2023) - NeoGenomics, Inc. (NASDAQ: NEO) (the “ Company ” ), a leading oncology testing services company, today announced its third-quarter
  evidence_url: https://www.sec.gov/Archives/edgar/data/1077183/000107718323000136/0001077183-23-000136-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.